# Researchers Reverse Aging in Donated Livers, Expanding Transplant Window
Surgeons face a brutal constraint: once a liver leaves a donor's body, degradation accelerates rapidly. Cold storage buys only hours before cellular damage becomes irreversible. Now researchers have demonstrated that perfusing livers with specific biological compounds can reverse some aging markers and potentially extend the transplant window significantly.
The technique addresses a critical bottleneck in organ transplantation. Approximately 17,000 people in the United States alone wait for liver transplants. Many never receive one. Donor livers have limited shelf life. Standard preservation protocols—flushing with preservative solution, packing in ice—merely slow decay rather than stop it. Organs deemed too damaged or aged become unsuitable for transplant. This shortage forces impossible medical choices daily.
The new approach perfuses donor organs with compounds that appear to reset some biological aging processes. Rather than passive cooling, the technique actively repairs cellular machinery during the critical hours between extraction and transplantation. Early results show livers treated this way exhibit reduced markers of age-related damage compared to conventionally preserved organs. The biological age appears younger after treatment than before extraction.
This work builds on perfusion technology that has slowly gained traction over the past decade. Normothermic perfusion—maintaining organs at body temperature while circulating oxygenated blood substitutes—has shown promise but requires complex equipment and careful monitoring. The new approach appears simpler while targeting the root problem: cellular senescence and mitochondrial dysfunction that accumulates during cold storage.
The implications ripple across transplantation broadly. Extended preservation windows mean livers can travel farther. Rural transplant centers gain access to more donor organs. Surgeons get more time to prepare recipients and coordinate complex procedures. The bottleneck loosens. Every additional hour matters when organs degrade exponentially over time.
Success rates for older donor livers remain lower than for younger organs. Transplant teams frequently reject livers from donors over 60, considering them too risky for standard recipients. If this technique truly reverses aging markers, previously rejected organs might become viable. A 70-year-old liver treated to appear 40 years old biologically could expand the usable donor pool dramatically.
The research comes from MIT's labs, though the exact compounds and mechanisms remain proprietary at this stage. Peer review and validation through independent groups will determine whether these results hold under scrutiny. Real-world transplantation involves hundreds of variables. Laboratory success does not guarantee clinical effectiveness.
Translation to clinical use requires regulatory approval and validation in human trials. The FDA pathway involves demonstrating safety and efficacy before hospitals can adopt the technique. Insurance coverage and cost considerations follow. Yet the potential justifies the development timeline. Even modest improvements in liver availability could save hundreds of lives annually.
Organ shortage drives innovation relentlessly. Researchers pursue xenotransplantation, artificial organs, and now biological rejuvenation of existing organs. Each approach addresses the same fundamental problem from different angles. This work suggests that within the existing donor pool, biology offers more flexibility than previously understood. The aging process itself may be partially reversible during preservation, offering a new lever for extending organ viability.